Abstract:6026 Background: The transformed growth factor beta (TGF-β) signaling pathway is dysregulated in carcinogenesis. In NPC patients, upregulation of TGF-β pathway is correlated with disease stage or phenotype due to Epstein-Barr virus (EBV) infection. GFH018, a novel TGF-βRI inhibitor, can inhibit tumor growth through inhibiting the activity of TGF-βRI kinase to block the signal transduction of TGF-β and modulate the tumor immune microenvironment. Preclinical studies showed that GFH018 in combination with PD-1/PD-L1 monoclonal antibody can significantly inhibit tumor growth synergistically. Here we report the preliminary results of combining GFH018 and Toripalimab treating R/M NPC patients (pts). Methods: This is a phase Ib/II study to evaluate the safety and efficacy of the combination of GFH018 and Toripalimab in pts with advanced solid tumors. Patients with RM NPC were enrolled to receive GFH018 80mg twice a day (BID) 14-day-on/14-day-off in combination with Toripalimab 3mg/kg every two weeks. Tumor assessment was performed every 8 weeks per Response Evaluation Criteria in Solid Tumor (RECIST) 1.1. Results: As of 31 Dec 2022, 32 pts with R/M NPC who had progressed on at least one prior line therapy were enrolled. Sixteen (50%) had received ≥3 lines of prior therapies, and 19 (59.4%) had previously received immune checkpoint inhibitors (ICIs) and platinum-based chemotherapies. The median duration of study drug exposure was 7 weeks. Twenty-five pts (78.1%) experienced treatment-related adverse events (TRAEs) of any grades, and 11 pts (34.4%) had ≥ Grade 3. The most common TRAEs (occurring in ≥ 3 pts) were anaemia (n = 6, 18.8%), hyponatraemia (n = 6, 18.8%), rash (n = 6, 18.8%), fatigue (n = 4, 12.5%), white blood cell count decreased (n = 4, 12.5%), aspartate aminotransferase increased (n = 3, 9.4%), back pain (n = 3, 9.4%), decreased appetite (n = 3, 9.4%), hypokalaemia (n = 3, 9.4%), and hypothyroidism (n = 3, 9.4%). As of 18 Jan 2023, among the 27 pts with post-baseline tumor assessments, 8 achieved partial response (PR), and 5 stable disease (SD); the overall response rate (ORR) was 29.6%, and disease control rate (DCR) was 48.1%. Six PR and 2 SD were observed among the 12 pts without prior treatment of ICIs; the ORR was 50%, and DCR was 66.7%. Four pts discontinued treatment without any post-baseline tumor assessments due to AEs or withdrawal of consent, and 1 patient is premature for tumor assessment. Conclusions: GFH018 combined Toripalimab was well tolerated and demonstrated preliminary efficacy in pts with R/M NPC. Specifically, in pts who had not previously received ICIs, promising antitumor activity was observed supporting further investigation to this group of pts. Clinical trial information: NCT04914286 .

Early growth response protein-1 promoter-mediated synergistic antitumor effect of hTERTC27 gene therapy and 5-Flurorouracil on nasopharyngeal carcinoma.

Suppressing Tumor Growth of Nasopharyngeal Carcinoma by Htertc27 Polypeptide Delivered Through Adeno-Associated Virus Plus Adenovirus Vector Cocktail

Radiofrequency Hyperthermia-Enhanced Herpes Simplex Virus-Thymidine Kinase/ganciclovir Direct Intratumoral Gene Therapy of Hepatocellular Carcinoma

4:10 PM Abstract No. 50 Intratumoral Radiofrequency Hyperthermia-Enhanced Herpes Simplex Virus Thymidine Kinase (HSV-TK) Gene Therapy of Orthotopic Lung Cancer Through the Augmentation of Apoptosis and Heat Shock Protein (HSP70) Expression Pathway

Combined Treatment of Cholangiocarcinoma with Interventional Radiofrequency Hyperthermia and Heat Shock Protein Promoter-Mediated HSV-TK Gene Therapy.

The combination of suicide gene therapy and radiation enhances the killing of nasopharyngeal carcinoma xenographs

Ferumoxytol and CpG Oligodeoxynucleotide 2395 Synergistically Enhance Antitumor Activity of Macrophages Against NSCLC with EGFR(L858R/T790M) Mutation

Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models.

Enhanced Antitumor Effect of Combining Interferon Beta with TRAIL Mediated by Tumor-Targeting Adeno-Associated Virus Vector on A549 Lung Cancer Xenograft.

Synergistic antitumor effect of puerarin combined with 5-fluorouracil on gastric carcinoma

Combination Therapy of Pancreatic Cancer with Tumor Necrosis Factor Alpha Gene and 5-Fluorouracil

Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells

Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier‐Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor

Antitumor effects of erlotinib in combination with berberine in A431 cells

Synergistic Effects of Nanosecond Pulsed Electric Fields Combined with Low Concentration of Gemcitabine on Human Oral Squamous Cell Carcinoma in Vitro

Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine

Therapeutic Efficacy of Epidermal Growth Factor Receptor Monoclonal Antibody Combined with Concurrent Chemoradiotherapy in Treatment of Locally Advanced Cervical Cancer.

Antiproliferative Effects on Non-Small Cell Lung Cancer Cells by Combining Tamoxifen and Gefitinib

A Phase Ib/II Study of GFH018 in Combination with Toripalimab in Recurrent/metastatic Nasopharyngeal Carcinoma (R/M NPC).

Antitumor Effects of a Dual-Specific Lentiviral Vector Carrying the Escherichia Coli Purine Nucleoside Phosphorylase Gene.

Erlotinib enhanced chemoradiotherapy sensitivity via inhibiting DNA damage repair in nasopharyngeal carcinoma CNE2 cells